TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31366262

Group type: EXPERIMENTAL
Intervention: Alogliptin (once-daily DPP-4i)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trelagliptin (once-weekly DPP-4i)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments (Alogliptin and Trelagliptin)
Number of subjects: 60
Study: 29894598

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI) treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 63
Study: 27510533

Group type: COMPARATOR
Intervention: Nonalkalized cocoa mixture containing 0.6 mg epicatechin, 0.2 mg catechin, and 2.9 mg monomer-decamer procyanidins/kg body weight
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of epicatechin and nonalkalized cocoa mixture containing 1.6 mg epicatechin/kg body weight
Number of subjects: 28
Study: 24476418

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin with concomitant azithromycin
Number of subjects: 263

Group type: COMPARATOR
Intervention: Inhaled aztreonam lysine
Number of subjects: 263

Group type: COMPARATOR
Intervention: Inhaled tobramycin without azithromycin
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: In vitro testing of P. aeruginosa isolates
Number of subjects: 263
Study: 22626813

Group type: EXPERIMENTAL
Intervention: I-gel prewarmed to 37 °C
Number of subjects: 180

Group type: COMPARATOR
Intervention: I-gel kept at room temperature (approximately 20 °C)
Number of subjects: 180
Study: 20724949

Group type: EXPERIMENTAL
Intervention: Oral L-arginine supplementation (0.1, 0.2, and 0.4 g/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (Healthy Controls)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral L-arginine supplementation
Number of subjects: 22
Study: 18597900

Group type: EXPERIMENTAL
Intervention: Intranasal live attenuated influenza vaccine (LAIV)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Intramuscular trivalent inactivated influenza vaccine (TIV)
Number of subjects: 243
Study: 15116063

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11487753

Group type: EXPERIMENTAL
Intervention: High iron formula (20.7 mg iron/L)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal iron formula (13.4 mg iron/L)
Number of subjects: 58
Study: 9724157

Group type: EXPERIMENTAL
Intervention: 2 g cefotiam
Number of subjects: 84

Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 84
Study: 8279610

Group type: EXPERIMENTAL
Intervention: Individually tailored mammography recommendation letters
Number of subjects: 435

Group type: COMPARATOR
Intervention: Standardized mammography recommendation letters
Number of subjects: 435
Study: 2918287

Group type: EXPERIMENTAL
Intervention: Commercial urine assays for detection of cocaine use
Number of subjects: 0

Group type: COMPARATOR
Intervention: KDI Quik Test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gas chromatography/mass spectrometry (GC/MS)
Number of subjects: 0
Study: 801345

Group type: EXPERIMENTAL
Intervention: Beconase (beclomethasone diproprionate)
Number of subjects: 32
Study: 31296251

Group type: EXPERIMENTAL
Intervention: Vitamin C (50 mg/kg) and thiamine (200 mg) administered intravenously every 12 hours for 48 hours
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (0.9% saline) administered in identical volume and manner as the treatment group
Number of subjects: 116
Study: 28596642

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg daily for 3 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24633992

Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation (LKM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 38
Study: 22832536

Group type: EXPERIMENTAL
Intervention: Slow movement and tonic force generation (LST; 3-s eccentric, 3-s concentric, and 1-s isometric actions with no rest between repetitions)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal speed (LN; 1-s concentric and 1-s eccentric actions with 1-s rests between repetitions)
Number of subjects: 35
Study: 21939502

Group type: EXPERIMENTAL
Intervention: Benchmarking group
Number of subjects: 3994

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3994
Study: 19108791

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg plus lisinopril 5 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Atenolol 25 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Lisinopril 5 mg
Number of subjects: 47
Study: 16813787

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 19
Study: 16258445

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy and radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomized trials
Number of subjects: 0
Study: 11780728

Group type: EXPERIMENTAL
Intervention: Tracking task at three different levels of task difficulty
Number of subjects: 12
Study: 9418187

Group type: EXPERIMENTAL
Intervention: Killed streptococcal preparation (KSP), low doses administered before and during early pregnancy.
Number of subjects: 228

Group type: COMPARATOR
Intervention: Paternal lymphocyte immunotherapy (control group).
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cell activity assessment.
Number of subjects: 228
Study: 8270363

Group type: EXPERIMENTAL
Intervention: Ampicillin plus cefotaxime or aminoglycoside (N=17)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ampicillin plus aminoglycoside (N=59)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy newborns (N=45)
Number of subjects: 62
Study: 3094846

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cyclosporine (high blood level)
Number of subjects: 122
Study: 31811383

Group type: EXPERIMENTAL
Intervention: Group 1 (endoscope introduced between the septum and inferior turbinate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 2 (endoscope introduced between the inferior turbinate and middle turbinate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group 1 and Group 2
Number of subjects: 60
Study: 30502982

Group type: EXPERIMENTAL
Intervention: Phaco-AIT (ab interno trabeculectomy with Trabectome combined with cataract surgery)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Phaco-Trab (Trabeculectomy with mitomycin C combined with cataract surgery)
Number of subjects: 19
Study: 26428322

Group type: EXPERIMENTAL
Intervention: Insertion of an external ventricular drain
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Increasing volume of cerebrospinal fluid (CSF) drainage per day
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Daily CSF output threshold of 78 mL
Number of subjects: 413

Group type: COMPARATOR
Intervention: Overall VPS insertion rate among 41,789 patients with aSAH from 66 studies
Number of subjects: 413
Study: 24884422

Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate 2.5%
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate 1%
Number of subjects: 411

Group type: COMPARATOR
Intervention: Hydrocortisone acetate 0.5%
Number of subjects: 411
Study: 23275415

Group type: EXPERIMENTAL
Intervention: Multiple oppositions approach (3 times per week for 8 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Multiple oppositions approach (once weekly for 24 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control condition (storybook intervention)
Number of subjects: 54
Study: 20708511

Group type: EXPERIMENTAL
Intervention: Ultrasonic filing (with PL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ultrasonic filing (without PL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hand filing (with PL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hand filing (without PL)
Number of subjects: 32
Study: 18469735

Group type: EXPERIMENTAL
Intervention: Playstation EyeToy Games
Number of subjects: 20
Study: 15672427

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 53

Group type: COMPARATOR
Intervention: CT
Number of subjects: 53
Study: 14698649

Group type: EXPERIMENTAL
Intervention: Endotoxin injection (2 ng/kg)
Number of subjects: 9
Study: 10554799

Group type: EXPERIMENTAL
Intervention: Itraconazole (5 mg/kg/d)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Fluconazole (100 mg)
Number of subjects: 581
Study: 8665036

Group type: EXPERIMENTAL
Intervention: Inhaled heparin (1,000 U/kg/dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2059298

Group type: EXPERIMENTAL
Intervention: Triple therapy (low-dose cyclosporin A, low-dose methylprednisolone, azathioprine)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Aza and CyA (double drug treatment)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Aza and MP (double drug treatment)
Number of subjects: 128

Group type: COMPARATOR
Intervention: CyA and MP (double drug treatment)
Number of subjects: 128
Study: 3841079

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 104
Study: 30066148

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study: 27523921

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 μg)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 μg)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 390
Study: 24140166

Group type: EXPERIMENTAL
Intervention: Melatonin (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study: 22378657

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg daily at bedtime)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20733210

Group type: EXPERIMENTAL
Intervention: External visual imagery with high self-enhancement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internal visual imagery with high self-enhancement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low narcissists across self-enhancement conditions
Number of subjects: 0
Study: 18561728

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (1 x 10 mg/kg, then 2 x 5 mg/kg at 24‐hour intervals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral indomethacin (3 x 0.2 mg/kg at 24‐hour intervals)
Number of subjects: 20
Study: 17605699

Group type: EXPERIMENTAL
Intervention: Educational Quality Use of Medicines program (academic detailing, prescribing information, feedback, medication risk assessment, medication review facilitation, financial incentives)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Educational Quality Use of Medicines program
Number of subjects: 849
Study: 15564950

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (3 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11111068

Group type: EXPERIMENTAL
Intervention: 0.3 mg per hour sustained-release polymer vaginal prostaglandin E(2) insert
Number of subjects: 24
Study: 9486510

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg IV post-partum, followed by 10 mg at 12 h and 10 mg at 24 h, total 30 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no corticosteroids)
Number of subjects: 34
Study: 8397516

Group type: EXPERIMENTAL
Intervention: High-fat diet (50% of energy)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dietary fiber content (2 or 4 g/MJ)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fibrinolytic variables (t‐PA and PAI‐1 antigen, PAI activity, t‐PA and euglobulin fibrinolytic activity)
Number of subjects: 6
Study: 3486546

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg, 2 ml) injected i.v. after arm exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (2 ml) injected i.v. after arm exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Muscle exercise (20 min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low frequency TNS (30 min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Face stimulation (low frequency TNS)
Number of subjects: 11
Study: 29900538

Group type: EXPERIMENTAL
Intervention: High molecular weight (HMW) adiponectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HMW adiponectin <1.53 μg/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasting glucose (FG) and maternal factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HMW adiponectin
Number of subjects: 0

Group type: COMPARATOR
Intervention: FG and maternal factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omentin-1 and IL-6
Number of subjects: 0
Study: 29415841

Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST) recommendations for viscosity
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST) recommendations for volume
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST) overall prevalence of OD
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST) PABAK
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Volume-Viscosity Swallow Test (V-VST) mean time to perform the test
Number of subjects: 110
Study: 26197846

Group type: EXPERIMENTAL
Intervention: rmPCR
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: rmPCR/AS
Number of subjects: 617

Group type: COMPARATOR
Intervention: Control
Number of subjects: 617
Study: 22231540

Group type: EXPERIMENTAL
Intervention: Balneotherapy (hot spring immersion at 40°C for 10 min daily for 2 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (daily shower)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Balneotherapy (hot spring immersion)
Number of subjects: 32
Study: 21921573

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy under combined spinal-epidural anesthesia (CSEA)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy under general anesthesia (GA)
Number of subjects: 64
Study: 19633594

Group type: EXPERIMENTAL
Intervention: Closed safe intravenous system (COSMOS - Compact Closed System)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open system (Mounted Open System)
Number of subjects: 0
Study: 15967695

Group type: EXPERIMENTAL
Intervention: Nasal histamine (8 mg/ml, 0.1 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intranasal saline challenge
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nasal histamine followed by intensified nasal and mouth breathing
Number of subjects: 20
Study: 14689348

Group type: EXPERIMENTAL
Intervention: Tafenoquine (400 mg daily for 3 days, then 400 mg every 4 weeks for 5 months)
Number of subjects: 104
Study: 11054066

Group type: EXPERIMENTAL
Intervention: Interphase fluorescence in situ hybridization (IFISH)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional marrow cytogenetic karyotype
Number of subjects: 64
Study: 9323645

Group type: EXPERIMENTAL
Intervention: Fatigue-based protocol using surface EMG during isometric contraction at 80% of maximal voluntary contraction (MVC) force
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of new test procedures for EMG parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model to predict MVC from anthropometrical measurements
Number of subjects: 0
Study: 7679885

Group type: EXPERIMENTAL
Intervention: Cold therapy (Hot/Ice Thermal Blanket) applied to 13 patients
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 27
Study: 3763140

Group type: EXPERIMENTAL
Intervention: Modified grid argon (blue-green) laser photocoagulation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 92
Study: 31182217

Group type: EXPERIMENTAL
Intervention: FamLit intervention (multi-component, family-focused, literacy-sensitive)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Attention-only intervention (control group)
Number of subjects: 43
Study: 29037884

Group type: EXPERIMENTAL
Intervention: Drainage group (A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-drainage group (B)
Number of subjects: 108
Study: 27466222

Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft (Auto group)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Irradiated hamstring tendon allograft (Ir-Allo group)
Number of subjects: 107
Study: 24401802

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) with ropivacaine 0.75%, 30 ml at time 0 and isotonic saline after 45 min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Adductor canal block (ACB) with isotonic saline at time 0 and ropivacaine 0.75%, 30 ml after 45 min
Number of subjects: 50
Study: 22743177

Group type: EXPERIMENTAL
Intervention: Triiodothyronine supplementation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Preoperative cytokine levels
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Postoperative cytokine levels
Number of subjects: 76
Study: 20610587

Group type: EXPERIMENTAL
Intervention: GnRH agonist (leuprolide acetate, 7.5 mg im every 28 d)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo injections (control)
Number of subjects: 41
Study: 18044260

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg) plus voglibose
Number of subjects: 31

Group type: COMPARATOR
Intervention: Voglibose alone
Number of subjects: 31
Study: 16583834

Group type: EXPERIMENTAL
Intervention: Cefotaxime prophylaxis
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 1000
Study: 11478566

Group type: EXPERIMENTAL
Intervention: Multi-component parenting intervention
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Retention strategies (incentives, tracking, culturally competent staff)
Number of subjects: 286
Study: 9621668

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with low dose fentanyl (8 micrograms.kg‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High dose fentanyl anesthesia (100 micrograms.kg‐1)
Number of subjects: 40
Study: 7871354

Group type: EXPERIMENTAL
Intervention: Suscard (lactose-containing nitroglycerin tablet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sucrose-containing lozenge (control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal oral hygiene procedures
Number of subjects: 12
Study: 3268159

Group type: EXPERIMENTAL
Intervention: Negative four-vessel angiography
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Appropriate limited angiography
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Initial CT scanning (abnormal)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: CT abnormalities
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 148
Study: 29996082

Group type: EXPERIMENTAL
Intervention: H4:IC31 vaccine
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 990

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990
Study: 25967068

Group type: EXPERIMENTAL
Intervention: Permethrin-treated pants
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-treated pants (control group)
Number of subjects: 82
Study: 25447444

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion 2 mg/kg/h after bolus 1.5 mg/kg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Combined infusion of lidocaine and dexmedetomidine
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 153
Study: 21951549

Group type: EXPERIMENTAL
Intervention: Octreotide SC, 500 μg three times daily for 7 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo SC for 7 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Open-label octreotide LAR 30 mg offered to all responders on day 14
Number of subjects: 15
Study: 20224901

Group type: EXPERIMENTAL
Intervention: SEIQoL-DW intervention administered 3-5 times per patient
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SEIQoL-DW intervention
Number of subjects: 13
Study: 17905013

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy plus large-balloon dilation (12- to 20-mm balloon diameter)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy alone
Number of subjects: 200
Study: 16037891

Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 36
Study: 12160281

Group type: EXPERIMENTAL
Intervention: Stapedectomy revision in elderly patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stapedectomy revision in younger patients (control group)
Number of subjects: 120
Study: 10660149

Group type: EXPERIMENTAL
Intervention: rIFN‐alpha2a
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8638799

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1325831

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg o.d.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg o.d.
Number of subjects: 21
Study: 6441542

Group type: EXPERIMENTAL
Intervention: Dipyridamole (300 mg/day) and low dose aspirin (150 mg/day) until delivery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 100
Study: 31265476

Group type: EXPERIMENTAL
Intervention: Supervised home-based physical exercise (2-3 sessions per week for 2-3 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Self-administered exercise program
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard care group (control)
Number of subjects: 23
Study: 29356827

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention (diet, exercise, cognitive training, and vascular risk management)
Number of subjects: 1109

Group type: COMPARATOR
Intervention: General health advice (Control)
Number of subjects: 1109